A otype-directed comparative ffectiveness ral of Buindolol and metoprolol succinate for prevention of symptomatic trial ibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial - 12/05/18
, Stuart J. Connolly, MD b, William T. Abraham, MD c, Jeff S. Healey, MD b, Benjamin A. Steinberg, MD, MHS d, Hussein R. Al-Khalidi, PhD a, Patricia Dignacco, BS a, Dirk J. van Veldhuisen, MD, PhD e, William H. Sauer, MD f, Michel White, MD g, Stephen B. Wilton, MD g, Inder S. Anand, MD, PhD h, Christopher Dufton, PhD i, Debra A. Marshall, MD i, Ryan G. Aleong, MD f, i, Gordon W. Davis, MSPH i, Richard L. Clark, PhD j, Laura L. Emery, MSPH i, Michael R. Bristow, MD, PhD i, kAbstract |
Background |
Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype). The safety and efficacy of bucindolol for the prevention of AF or atrial flutter (AFL) in these patients has not been proven in randomized trials.
Methods/design |
The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded “seamless” phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF). Patients with pre-existing HFrEF and recent history of symptomatic AF are eligible for enrollment and genotype screening, and if they are ADRB1 Arg389Arg, eligible for randomization. A total of approximately 200 patients will comprise the phase 2B component and if pre-trial assumptions are met, 620 patients will be randomized at approximately 135 sites to form the Phase 3 population. The primary endpoint is the time to recurrence of symptomatic AF/AFL or mortality over a 24-week follow-up period, and the trial will continue until 330 primary endpoints have occurred.
Conclusions |
GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype. (ClinicalTrials.gov NCT01970501).
Le texte complet de cet article est disponible en PDF.Plan
| RCT# NCT01970501 |
|
| W. H. Wilson Tang, MD served as guest editor for this article. |
Vol 199
P. 51-58 - mai 2018 Retour au numéro
Article précédent
- Rationale and design of a trial to personalize risk assessment in familial coronary artery disease
- Thomas H Marwick, Kristyn Whitmore, Stephen J Nicholls, Tony Stanton, Geoffrey Mitchell, Andrew Tonkin, Christopher Blizzard, Amanda Neil, Catherine Jones, Gerald F Watts, CAUGHT-CAD Investigators
- Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial
- Harriette G.C. Van Spall, Shun Fu Lee, Feng Xie, Dennis T. Ko, Lehana Thabane, Quazi Ibrahim, Peter R. Mitoff, Michael Heffernan, Manish Maingi, Michael C. Tjandrawidjaja, Mohammad I. Zia, Mohamed Panju, Richard Perez, Kim D. Simek, Liane Porepa, Ian D. Graham, R. Brian Haynes, Dilys Haughton, Stuart J. Connolly
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?